Thyrocare Q1 consolidated PAT up 34% YoY to ₹51 Cr on 24% revenue growth, margins expand
PAT +34.06% YoY · revenue +24.34% · margins expanding · beat vs street
₹240.02 Cr
+24.34% YoY
₹51.33 Cr
+34.06% YoY
21.02%
+1.6pp YoY
₹3.23
Thyrocare Technologies opened FY27 with a broad-based beat: consolidated revenue from operations rose 24.3% YoY to ₹240.02 Cr and profit for the period grew 34.1% to ₹51.33 Cr (owners' share ₹52.19 Cr), with net margin firming to ~21.4% from 19.4% a year ago. The print runs comfortably ahead of the 'mid- to high-teens' revenue growth management guided on the Q4 concall and the 15–22% FY27 PAT growth analysts were modelling, and confirms the confident, volume-led tone (75% volume / 25% mix, no price hikes) set on that call. Standalone tells the same story — revenue +26.1% to ₹225.66 Cr, PAT +39.2% to ₹50.17 Cr — so there is no divergence between the two bases.
Q1 FY-2027 vs prior quarters
The engine is the core diagnostic testing business: segment revenue rose 26.9% YoY to ₹226.21 Cr and segment profit jumped ~38% to ₹61.90 Cr, driving the operating-margin expansion (OPM ~32.2% vs 29.9% YoY). Imaging remains the soft spot — revenue slipped to ₹13.48 Cr from ₹14.04 Cr and contributed a thin ₹1.26 Cr result. Against the prior quarter the picture is a sequential slowdown rather than acceleration: revenue is up only 7.2% and PAT up 5.4% QoQ, and headline OPM eased from Q4's 33.5%, consistent with management's stated intent to reinvest operating leverage back into growth rather than let it drop to margin, keeping normalized EBITDA around 34%.
The stock went into the print at ₹548.2, down 1.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Management has upwardly revised its revenue guidance to 'mid- to high teens' growth for the upcoming fiscal year, driven primarily by volume (75%) and mix (25%) with no planned price increases. The company expects to maintain its stable normalized EBITDA margin of around 34% by reinvesting any operating leverage back i
— This quarter: beat
The quarter also carried a cluster of governance actions: Price Waterhouse Chartered Accountants LLP reviewed these results as the newly appointed statutory auditor (per the 30 June appointment), EY was re-appointed internal auditor for FY27, and the board had earlier set a 23 June record date for the FY26 final dividend. One drag to watch is the subsidiary layer — unreviewed subsidiaries posted a ₹0.84 Cr comprehensive loss and non-controlling interest turned negative (₹0.86 Cr), which is why group profit for the period sits below the owners' share. Management's promised specialty-diagnostics foray (genomics, allergy) is not yet visible as a separate driver in this print.
W1
Whether revenue growth holds above the 'mid- to high-teens' FY27 guidance after a strong ₹240 Cr Q1
W2
Normalized EBITDA margin trajectory toward management's ~34% target vs the ~32.2% reported this quarter
W3
Imaging segment recovery — revenue slipped to ₹13.48 Cr; and first visible contribution from the specialty-diagnostics (genomics/allergy) foray
W4
Subsidiary drag — ₹0.84 Cr comprehensive loss and negative NCI keeping group profit below owners' share
Clean legible statements, both standalone & consolidated present. Consolidated PBT 68.29 includes ₹0.71 Cr share of associate profit; no exceptional items this quarter (FY26 full-year had ₹6.16 Cr exceptional, not in comparison quarters). Profit for period ₹51.33 Cr used as PAT for DB consistency; owners' share is higher at ₹52.19 Cr because non-controlling interest booked a ₹0.86 Cr loss (subsidiaries posted a ₹0.84 Cr comprehensive loss). EPS not annualised. Prior-year EPS restated for bonus issue (context ₹7.35 pre-bonus vs ₹2.41 restated).
Informational and educational content only. Not investment advice.